2025 MIDD Webinar Series | Navigating regulatory interactions for a pivotal study with population PK model-predicted metric as a co-primary endpoint: case study of subcutaneous administration of atezolizumab

2025 MIDD Webinar Series | Navigating regulatory interactions for a pivotal study with population PK model-predicted metric as a co-primary endpoint: case study of subcutaneous administration of atezolizumab

Includes a Live Web Event on 07/16/2025 at 12:00 PM (EDT)

The MIDD Webinar Series, coordinated by Yash Kapoor and Fulya Akpinar Singh, is a series of webinars focused on shaping the future of drug development and regulatory decision-making sponsored by the ISoP Education Committee. Topics range from MIDD approaches in regulatory submission to pharmacometrics topics that are at the core of model development.  

Phyllis Chan

Pharmacometrician in Clinical Pharmacology Modeling & Simulation Group

Genentech

Phyllis is a pharmacometrician in the Clinical Pharmacology Modeling & Simulation group at Genentech in South San Francisco. Before joining Genentech in 2017, Phyllis worked at Bristol-Myers Squibb, obtained her PhD in Pharmaceutical Sciences from Auburn University and was a postdoctoral fellow at University of Southern California's Biomedical Simulations Resource (BMSR).  More recently, Phyllis received an MPH from Imperial College London.  She specializes in population PK, exposure-response, tumor growth inhibition-overall survival, and model-based meta-analysis.

Key:

Complete
Failed
Available
Locked
MIDD Series | Navigating regulatory interactions for a pivotal study with population PK model-predicted metric as a co-primary endpoint: case study of subcutaneous administration of atezolizumab
07/16/2025 at 12:00 PM (EDT)  |  60 minutes
07/16/2025 at 12:00 PM (EDT)  |  60 minutes
You must register to access.